Cardiovascular Peptides Market Driven by Elevated Side Effects of Existing Cardiovascular Products

The global peptides market is growing at a healthy rate. This, in turn, will drive the global cardiovascular peptides market. The global peptides therapeutics market has developed at a notable rate in the recent past. This has led to an unparalleled growth in the number of regulatory approvals obtained in 2012. This elevated the number of approved peptide-based drug products and expanded the range of medical indications on which peptides could be used, boosting the maturity of peptides as a class of pharmaceutical products.

Global Cardiovascular Peptides Market to Benefit from Rising Prevalence of Cardiovascular Conditions

Cardiovascular peptides are commonly produced in the heart, while many other tissues in the body produce it in too low an amount to have any physiological effect. Improvements in biotechnology, along with pharmaceutical sciences, have enabled scientists to mimic or modify naturally occurring peptides for various therapeutic uses.

According to the WHO, around 17.3 million people died due to cardiovascular conditions in 2008, which represents approximately 30% of all the global deaths. The WHO further says that the number of deaths globally due to cardiovascular conditions is projected to reach 30 million by 2030. The global cardiovascular peptides market is primarily driven by the growing prevalence of cardiovascular conditions and other associated conditions such as obesity. Furthermore, the serious side effects associated with available cardiovascular products are also driving the global cardiovascular peptides market.

On the other hand, the high cost of development of cardiovascular peptides will suppress the global cardiovascular peptides market. In addition to this, the strict regulatory policies and approval procedures implemented by the FDA will hamper the growth of the global cardiovascular peptides market to some extent.

Request Brochure: http://www.transparencymarketresearch.com/cardiovascular-peptides-market.html

North America to Dominate Global Cardiovascular Peptides Market

Geography-wise, the global cardiovascular peptides market is divided into North America, Asia Pacific, Europe, and Rest of the World (RoW). North America is presently dominating the global cardiovascular peptides market, due to the high incidence of cardiovascular diseases, presence of insurance coverage, availability of sophisticated technologies, and elevated healthcare expenditure in the region.

In North America, heart failures or cardiac arrests are a rising public health concern, affecting millions of Americans every year. On the other hand, Asia Pacific will demonstrate a high growth rate in the global cardiovascular peptides market. India and China will fuel the Asia Pacific cardiovascular peptides market due to their large population base and rising geriatric population.

By major cardiovascular diseases, the global cardiovascular peptides market is divided into hematologic diseases, peripheral vascular diseases, hypertension, myocardial infarction, and heart failure. Several cardiovascular peptides are currently in clinical trials. For example, Danegaptide, a novel dipeptide, from Zealand is a powerful, selective gap junction modifier in Phase II, where it is being analyzed for its efficiency and safety in acute myocardial infarction (AMI) patients.

Several giants in the pharmaceutical industry have invested massively in research and development projects to explore the efficiency of cardiovascular peptides. Some of the key companies operating in the global cardiovascular peptides market are Eli Lilly & Company, Novartis, Novo Nordisk, Takeda Pharmaceutical, AstraZeneca, Zealand Pharma, GlaxoSmithKline, and American Peptide Company.

Browse Full Global Cardiovascular Peptides Market Report With Complete TOC @ http://www.transparencymarketresearch.com/cardiovascular-peptides-market.html